XPEV XPeng Inc tops Q4 2025 EPS estimates by wide margin shares climb nearly 5 percent on upbeat investor reaction Crown Castle Inc CCI Q1 2026 Profit Turnaround Asset Divestiture Progress and Reaffirmed FullYear Guidance Signal Strategic Pivot Trajectory Sangamo Therapeutics SGMO Stock Momentum Analysis Sangamo Therapeutics posts 797 downside EPS miss